LON:HEMO Hemogenyx Pharmaceuticals 4/28/2025 Earnings Report GBX 144.28 -0.73 (-0.50%) As of 07/11/2025 11:49 AM Eastern ProfileEarnings History Hemogenyx Pharmaceuticals EPS ResultsActual EPS-GBX 181.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHemogenyx Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHemogenyx Pharmaceuticals Announcement DetailsQuarterDate4/28/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Hemogenyx Pharmaceuticals Earnings HeadlinesHemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director's DealingJune 4, 2025 | finance.yahoo.comTRADING UPDATES: Valereum invests in Blubird; Hemogenyx raises fundsJune 4, 2025 | lse.co.ukPresident Trump’s Project MAFAPresident Trump’s Boldest Initiative Yet First came “Make America Great Again” (MAGA)… Then came “Make America Healthy Again” (MAHA)… Now comes President Trump’s boldest initiative yet. After a gathering in D.C. with some of the most powerful people in the world, Jeff Brown is now revealing the full details on “Project MAFA.” It’s a revolutionary plan to return America to an era of sound money, eliminate our looming debt disaster, kick off a Golden Century, and more – by July 25. Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%. Jeff Brown is sharing the details Wednesday, July 16, at 8 p.m. ET – including the name of a stock set to profit.July 13 at 2:00 AM | Brownstone Research (Ad)This Hemogenyx Pharmaceuticals Insider Increased Their Holding By 241% Last YearMay 16, 2025 | finance.yahoo.comTRADING UPDATES: Golden Rock secures refinancing; tinyBuild makes saleApril 4, 2025 | lse.co.ukHemogenyx Pharmaceuticals Boosts Clinical Trials with £340,000 FundraisingJanuary 8, 2025 | markets.businessinsider.comSee More Hemogenyx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hemogenyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemogenyx Pharmaceuticals and other key companies, straight to your email. Email Address About Hemogenyx PharmaceuticalsHemogenyx Pharmaceuticals (LON:HEMO), a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.View Hemogenyx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
